Fungal Diagnostics Journal Watch – June 2026

Posted on by

Reviewing recent developments in molecular diagnostics, biomarkers and rapid testing for invasive fungal disease

Introduction

The fungal diagnostics landscape continues to evolve rapidly. Molecular diagnostics, sequencing technologies and rapid antigen detection assays are increasingly supplementing traditional microscopy and culture, with growing incorporation into international diagnostic frameworks and clinical practice.

This month’s journal watch highlights five publications that collectively illustrate the direction of travel in fungal diagnostics. Together they reinforce a clear message: future diagnosis of invasive fungal disease will depend increasingly upon integrated interpretation of molecular, biomarker, radiological and clinical data.

Paper 1

British Society for Medical Mycology Best Practice Recommendations for the Diagnosis of Serious Fungal Diseases: 2025 Update

Schelenz S, Abdolrasouli A, Armstrong-James D, et al.
Lancet Infectious Diseases (2026)
PMID: 41232547

Background

The diagnosis of invasive fungal disease has changed substantially over the past decade. Antigen testing, serology and molecular methods now play increasingly important roles alongside conventional culture-based approaches.

Principal Findings

  • Strong emphasis on non-culture diagnostic approaches.
  • Recognition of molecular diagnostics as established components of fungal diagnostic pathways.
  • Integration of laboratory diagnostics with imaging and clinical assessment.
  • Comprehensive coverage of major invasive fungal diseases encountered in UK practice.

Clinical Significance

This publication formally recognises what many specialist centres have already implemented: fungal diagnosis is increasingly multimodal. The guidance reflects the maturation of fungal molecular diagnostics and provides an important framework for future service development across the UK.

Strengths and Limitations

  • Comprehensive UK expert consensus.
  • Broad clinical applicability.
  • Reflects current diagnostic technologies.
  • Evidence base remains stronger for some fungal diseases than others.

Implications for Fungal Diagnostic Services

Laboratories and specialist services will increasingly need access to integrated molecular, antigen and serological testing platforms in addition to traditional mycology capabilities.

Paper 2

Clinical and Analytical Evaluation of a Commercial Aspergillus fumigatus Real-Time PCR Assay for the Diagnosis of Invasive Pulmonary Aspergillosis in Patients with Haematological Malignancies

Gibert C, Bigot J, Brissot E, et al.
Journal of Infectious Diseases (2026)
PMID: 42217497

Background

Aspergillus PCR has been evaluated extensively through European Aspergillus PCR Initiative studies and subsequent validation work. However, continued assessment of commercial assays under routine clinical conditions remains important.

Principal Findings

  • 153 patients with haematological malignancies.
  • 296 serum specimens and 136 respiratory specimens analysed.
  • Sensitivity approximately 73%.
  • Specificity approximately 71%.
  • Diagnostic performance comparable to previous PCR studies.

Clinical Significance

This study provides further evidence supporting incorporation of Aspergillus PCR into multimodal diagnostic pathways for invasive pulmonary aspergillosis. The findings align with broader evidence supporting molecular testing within EORTC/MSGERC-aligned diagnostic frameworks.

Strengths and Limitations

  • Real-world clinical evaluation.
  • Commercial assay assessment.
  • Large number of clinical specimens.
  • Haematology-focused population may limit wider generalisability.

Implications for Fungal Diagnostic Services

The findings support continued expansion of Aspergillus PCR testing within specialist fungal diagnostic laboratories and reinforce its role as a complementary diagnostic modality rather than a standalone test.

Paper 3

Diagnostic Accuracy of Metagenomic Next-Generation Sequencing for Invasive Pulmonary Aspergillosis: A Systematic Review and Meta-analysis

Lv H, Jin S, Li L, et al.
International Journal of Infectious Diseases (2026)
PMID: 42208932

Background

Metagenomic next-generation sequencing offers the possibility of broad, untargeted pathogen detection directly from clinical specimens and is increasingly being explored in fungal diagnostics.

Principal Findings

  • Systematic review and meta-analysis.
  • Good overall diagnostic performance.
  • Bronchoalveolar lavage specimens performed best.
  • Potential utility in culture-negative disease and mixed infections.

Clinical Significance

Metagenomic next-generation sequencing remains one of the most promising emerging technologies in infectious disease diagnostics. Its greatest potential may lie in diagnostically challenging patients where conventional testing is inconclusive.

Strengths and Limitations

  • Comprehensive synthesis of available evidence.
  • Focus on clinically relevant invasive pulmonary aspergillosis.
  • Heterogeneity between included studies.
  • Cost and interpretation remain significant barriers.

Implications for Fungal Diagnostic Services

While widespread implementation remains some distance away, specialist centres should monitor developments closely. Future fungal reference laboratory services are likely to incorporate sequencing-based diagnostics.

Paper 4

Real-Life Performance of a Galactomannoprotein-Detecting Lateral Flow Immunoassay (AspLFD) in Lower Respiratory Tract and Serum Specimens for Screening Pulmonary Aspergillosis

Medina A, Clari MÁ, Tormo M, et al.
Diagnostic Microbiology and Infectious Disease (2026)
PMID: 42208190

Background

Rapid fungal diagnostics remain a major unmet need. Lateral flow technologies offer the possibility of shorter turnaround times and improved access to testing.

Principal Findings

  • Overall sensitivity of approximately 78%.
  • Evaluated in both respiratory and serum specimens.
  • Demonstrated utility as a rapid screening tool.

Clinical Significance

Although unlikely to replace comprehensive laboratory diagnostics, lateral flow assays may improve diagnostic accessibility and support earlier clinical decision-making.

Strengths and Limitations

  • Real-world clinical evaluation.
  • Rapid turnaround.
  • Single-centre study design.
  • Performance remains insufficient for use as a standalone diagnostic test.

Implications for Fungal Diagnostic Services

Rapid Aspergillus diagnostics may become increasingly important in settings where access to specialist molecular testing is limited.

Paper 5

Laboratory Diagnostics of Aspergillosis: Present State and Future Directions

Tomazin R, Matos T
Journal of Fungi (2026)
PMID: 42187861

Background

The expanding range of available diagnostic tests has increased both opportunities and complexity in Aspergillus diagnostics.

Principal Findings

  • Comprehensive review of galactomannan, β-D-glucan, PCR, lateral flow assays and sequencing technologies.
  • Highlights strengths and limitations of current approaches.
  • Emphasises integrated diagnostic interpretation.

Clinical Significance

The review provides an excellent summary of the current state of the field and reinforces the principle that no single test currently provides optimal performance across all clinical settings.

Strengths and Limitations

  • Comprehensive review of current diagnostics.
  • Broad clinical relevance.
  • Limited by available published evidence.

Implications for Fungal Diagnostic Services

Future diagnostic pathways are likely to combine molecular diagnostics, biomarkers, imaging and conventional microbiology within increasingly integrated decision-making frameworks.

Editorial Commentary

Taken together, these publications reinforce three major trends. First, fungal diagnosis is moving steadily away from reliance on culture alone. Second, molecular diagnostics are becoming embedded within routine practice rather than remaining specialist adjunctive tools. Third, future innovation is likely to come increasingly from sequencing technologies and rapid near-patient testing.

Perhaps the most important message is that fungal diagnostics are becoming increasingly integrated. Rather than searching for a single definitive test, the field is moving towards combining multiple complementary diagnostic modalities to improve overall diagnostic accuracy and support earlier treatment decisions.

Author: Graham Atherton
Organisation: National Aspergillosis Centre, Manchester University NHS Foundation Trust
Publication: MRCM.org.uk
Date: June 2026

Further Reading